



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

Seizure: European Journal of Epilepsy

journal homepage: www.elsevier.com/locate/seizure

Short communication

Safety of inactivated COVID-19 vaccine in tuberous sclerosis complex patients with epilepsy treated with rapamycin

Qian Lu^a, Yang-Yang Wang^a, Qiu-Hong Wang^a, Li-Na Tang^{a,b}, Xiao-Yan Yang^a, Shuo Dun^a, Li-Ping Zou^{a,c,*}

^a Senior Department of Pediatrics, Chinese PLA General Hospital, Department of Pediatrics, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China

^b Fosun Health, Beijing, China

^c Center for Brain Disorders Research, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China

ARTICLE INFO

Keywords:

COVID-19 vaccine
Tuberous sclerosis complex
Epilepsy
mTOR inhibitor
Rapamycin

ABSTRACT

Purpose: To assess the safety of inactivated coronavirus 2019 disease (COVID-19) vaccine in tuberous sclerosis complex (TSC) patients with epilepsy.

Methods: All patients with epilepsy were selected from Efficacy and Safety of Sirolimus in Pediatric Patients with Tuberous Sclerosis (ESOSPIT) project and younger than 17 years old. The patients were treated with mTOR inhibitors (rapamycin). A total of 44 patients who completed the two-dose inactivated COVID-19 vaccine between July 7, 2021, and January 1, 2022, were enrolled.

Results: The median age of seizure onset was 23 months. About two-thirds of patients have focal seizures. Thirty-three patients use antiseizure medications. The mean duration of rapamycin treatment was 55.59 ± 18.42 months. Adverse reactions within 28 days after injection occurred in 11 patients (25%), all were under 12 years old. Injection site pain was the most reported event (20.45%), which was mild in severity and improved within one day. All patients had no seizure-related changes after vaccination.

Conclusion: This study shows that the inactivated COVID-19 vaccine was well tolerated and safe in TSC patients with epilepsy, as well as for those treated with mTOR inhibitors.

1. Introduction

The World Health Organization (WHO) announced that as of March 2022, the number of confirmed coronavirus 2019 disease (COVID-19) cases had reached more than 438 million worldwide. Children of all ages are susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although most infected children are mild or asymptomatic, the multisystem inflammatory syndrome is still reported [1]. Infected children can also cause severe community transmission.

Vaccination and multiple preventive measures are the most effective ways to curb the spread of SARS-CoV-2 quickly. More than 140 candidate vaccines exist. CoronaVac and BBIBP-CorV (Beijing Institute of Biological Products, Beijing, China) are safe for children and adolescents

over three years old [2,3]. In June 2021, inactivated COVID-19 vaccine was recommended for children over three years old in China. The Pfizer/BioNTech vaccine is recommended for children over five years old in the United States and the United Kingdom. However, the hesitation of most parents to vaccinate due to concerns regarding the safety and adverse reaction of COVID-19 vaccines is a major global public health problem [4].

Tuberous sclerosis complex (TSC) is one of the most common rare diseases that affect multiple organ systems with an incidence rate of approximately 1/6000 [5]. Epilepsy develops in 80–90% of patients with TSC and often begins in the first year of life [5]. The safety of COVID-19 vaccines is the most concern for patients with epilepsy. mTOR inhibitor, such as rapamycin, is approved to treat TSC [5]. Rapamycin

Abbreviations: COVID-19, Coronavirus 2019 disease; WHO, World Health Organization; ESOSPIT, Efficacy and Safety of Sirolimus in Pediatric Patients with Tuberous Sclerosis; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; BBIBP-CorV, Beijing Institute of Biological Products; TSC, tuberous sclerosis complex; ASMs, antiseizure medications.

* Corresponding author at: Senior department of Pediatrics, Chinese PLA General Hospital, Department of Pediatrics, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.

E-mail address: zouliping21@hotmail.com (L.-P. Zou).

<https://doi.org/10.1016/j.seizure.2022.05.010>

Received 24 March 2022; Received in revised form 12 May 2022; Accepted 14 May 2022

Available online 16 May 2022

1059-1311/© 2022 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

has an immunosuppressive effect that is widely used in autoimmune diseases and organ transplantation. mTOR inhibitors reduce the replication of SARS-CoV-2 and become a potential drug for the treatment of COVID-19 [6]. It has been reported that seven patients with TSC on mTOR inhibitors had COVID-19 vaccinated without adverse reaction [7].

We assessed the safety of inactivated COVID-19 vaccine in pediatric TSC patients with epilepsy.

2. Material and methods

All patients were selected from the Efficacy and Safety of Sirolimus in Pediatric Patients with Tuberous Sclerosis (ESOSPIT) project of the Chinese Clinical Trial Registry (No. ChiCTR-OOB-15006535). We investigated children and adolescents younger than 17 years old with epilepsy who were diagnosed with TSC according to the 2012 International TSC Diagnostic Criteria [8]. The patients were administered 1 mg/(m²•d) rapamycin (Huangdong Medicine Co., Ltd. of Hangzhou), and dose was adjusted to attain a blood concentration of 5–10 ng/mL. The Ethics Committee of the Chinese PLA General Hospital (No. S2013-028-01) approved this study.

The patients were voluntarily injected with inactivated COVID-19 vaccine in accordance with the local vaccine supply. Two-dose vaccines were administered at an interval of 3–8 weeks. The inactivated COVID-19 vaccines were CoronaVac and BBIBP-CorV. The patients who had completed two-dose vaccines were included. Telephone follow-up was performed at 7 and 28 days after injection to collect information on seizures, medication, vaccine manufacturer, and adverse reactions after injection. Seizures were classified according to the latest International League Against Epilepsy (ILAE) guidelines [9]. Seizure frequencies were divided into four categories, ranging from once every day, once every month, at least once per year, and seizure-free over 1 year.

Adverse reactions related to inactivated COVID-19 vaccine included (a) injection site adverse reactions, such as pain, swelling, induration, erythema, and pruritus, and (b) systematic adverse reactions, such as fever, cough, headache, anorexia, vomiting, acute allergic, and seizure-related changes.

3. Results

A total of 76 patients with TSC received inactivated COVID-19 vaccine between July 7, 2021, and January 1, 2022. Seven patients who did not receive the second dose of vaccine due to the short time from the first dose were excluded. Ten patients without seizures were excluded. Fifteen patients were excluded due to the discontinuation of rapamycin. Forty-four patients were eventually enrolled in the study (Fig. 1A).

The age of the patients ranged from five to fifteen years with a mean of 9.62 ± 2.89 years (Table 1). The distribution of different age groups is shown in Fig. 1B. The male-to-female ratio was 1.16:1. The age of seizure onset ranged from one day to ten years with a median of 23 months. About two-thirds of patients have focal seizures. Two patients had seizures once per year. Four patients had seizures once every month. The other patients were seizure-free for more than a year. Ten patients did not use antiseizure medications (ASMs), 31 patients used less than two ASMs, and three patients used three ASMs (Table 1). The duration of rapamycin use ranged from 20 to 108 months with a mean of 55.59 ± 18.42 months.

A total of 31 patients underwent genetic testing. Eight patients had *TSC1* variants (NM_000368.4) and 17 patients had *TSC2* variants (NM_000548.3). No *TSC1* or *TSC2* variants were found in the other six patients. Among the 25 patients with gene variants, seven had missense variants, six had nonsense variants, and 12 had frameshift variants. One patient had two *TSC2* missense variants (c.4639G > A, c.4795G > A). The distribution of gene variants is shown in Fig. 1C.

Eleven of the 44 patients (25%) who received two-dose of inactivated COVID-19 vaccines had adverse reactions. The adverse reactions were all mild in severity. Injection site pain, which improved within one day, occurred in 9 patients (20.45%). One patient had injection site swelling. One patient had a fever (38 °C) four days after vaccination. No one had seizures within 28 days after vaccination.

In the 5–7 years old group, three patients had injection site pain, and one patient had injection site swelling. One patient had a fever. In the 8–11 years old group, six patients had injection site pain. In children older than 12 years, no one had adverse reactions (Fig. 1B).

Of the 18 patients who received two-dose of CoronaVac vaccines, two had injection site pain, and one had injection site swelling. Four of




Fig. 1. A: Flow diagram of the study patients. B: Age distribution of patients and incidence of adverse reactions at different ages. The three bars show three ages 5–7 years old, 8–11 years old, and 12–16 years old. Dark indicates the number of people with no adverse reactions and gray indicates the number of people with adverse reactions. Y: years. C: The distribution of *TSC1* and *TSC2* variants sites.

Table 1
Clinical characteristics of 44 patients.

	Number	Percentage		Number	Percentage
Age, years, mean±SD	9.62 ± 2.89	–	Number of antiseizure medications		
Age of seizure onset, months	23 (9.25, 48)	–	0	10	22.73
Gender, male	29	65.91	1–2	31	70.45
Seizure classification			≥3	3	6.82
Focal onset	29	65.91	Genetic variants		
Generalized onset	15	34.09	TSC1	8	18.18
Seizure frequency ranking			TSC2	17	38.64
Once every day	0	0	No variants	6	13.64
Once every month	4	9.09	Not perform	13	29.54
Once per year	2	4.55	Hypopigmentation	42	95.45
Over 1 year seizure free	38	86.36	Shagreen patches	19	43.18
Time of rapamycin treatment, months	55.59 ± 18.42	–	Angiofibroma	13	29.55
			Heart diseases	5	11.36
			Renal diseases	8	18.18

the 18 patients who received two-dose of BBIBP-CorV vaccines had injection site pain. Of the 8 patients who received two-dose of vaccines from different manufacturers, three had injection site pain, and one had a fever.

4. Discussion

This is the first report that inactivated COVID-19 vaccine is safe in TSC patients with epilepsy. All patients with epilepsy did not have seizure-related changes after vaccination in our study. It was reported that no evidence suggests worsening seizures after COVID-19 vaccination in adults [10]. Adverse reactions occurred in 25% of our patients. Similar to that in healthy children who received inactivated COVID-19 vaccine, the most common adverse reaction in our patients was the injection site pain. Adverse reactions after CoronaVac injection occurred in 29% of children and adolescents aged 3–17 years, and injection site pain, which was mild and moderate in severity, was the most common adverse reaction and occurred within seven days after injection [2]. The most common adverse reaction reported of BBIBP-CorV was also injection site pain, which mostly occurred in children under the age of 12 [3].

Our study showed that inactivated COVID-19 vaccine is safe for children and adolescents using rapamycin. As we all know, rapamycin has an immunosuppressive effect. SARS-CoV-2 infection occurred in an adult with TSC on mTOR inhibitor without serious adverse consequences [7]. Our patients who used rapamycin did not show increasing infection after vaccination. Recently, mTOR inhibitors have been found to have an immunomodulatory effect. Rapamycin treatment markedly enhanced the survival of CD8⁺T cells after infection and the recall response of CD8⁺T cells to secondary infection [11]. Low-dose mTOR inhibitor therapy in 264 healthy elderly people for 6 weeks not only enhanced the immune function and decreased infection rates but also up-regulated antiviral gene expression [12]. For other patients treated with mTOR inhibitors, such as autoimmune diseases, the safety of COVID-19 vaccines still needs further evaluation.

Homologous schedules are considered to be standard practice for each COVID-19 vaccine. However, the WHO supports a flexible approach to homologous versus heterologous vaccination schedules. Our eight patients who received inactivated vaccines from two manufacturers had no serious adverse reactions. About two-thirds of the population worldwide needs to be immunized to stop the spread of COVID-19. Further effort should be made to increase vaccination rates to prevent the spread of COVID-19.

5. Conclusion

Inactivated COVID-19 vaccine was well tolerated and safe in pediatric TSC patients with epilepsy, as well as for those treated with mTOR inhibitors. Mild adverse reactions occurred in 25% of the patients. The most common adverse reaction was injection site pain. All patients had

no seizure-related changes after vaccination. Additional efforts should be made to increase vaccination rates to prevent the spread of COVID-19.

CRediT authorship contribution statement

Qian Lu: Visualization, Data curation, Formal analysis, Writing – original draft, Writing – review & editing. **Yang-Yang Wang:** Data curation, Writing – review & editing. **Qiu-Hong Wang:** Data curation, Writing – review & editing. **Li-Na Tang:** Data curation, Formal analysis. **Xiao-Yan Yang:** Data curation, Writing – review & editing. **Shuo Dun:** Data curation, Writing – review & editing. **Li-Ping Zou:** Visualization, Formal analysis, Writing – review & editing, Data curation.

Declaration of Competing Interest

The authors declare that they have no competing interests.

Acknowledgment

We sincerely acknowledge the support of all of the participants who contributed to this study.

Funding/support

This study was funded by the National Key Research Program of China (Grant No. 2016YC1000700).

Availability of data

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

References

- [1] Alshohime F, Temsah MH, Al-Nemri AM, Somily AM, Al-Subaie S. COVID-19 infection prevalence in pediatric population: etiology, clinical presentation, and outcome. *J Infect Public Health* 2020;13:1791–6.
- [2] Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, Li M, Lian X, Jiao W, Wang L, Shu Q, Wu Z, Zhao Y, Li Q, Gao Q. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. *Lancet Infect Dis* 2021;21:1645–53.
- [3] Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet Infect Dis* 2021;21:39–51.
- [4] Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A. A global survey of potential acceptance of a COVID-19 vaccine. *Nat Med* 2021;27:225–8.

- [5] Henske EP, Józwiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. *Nat Rev Dis Prim* 2016;2:16035.
- [6] Mullen PJ, Garcia G, Purkayastha A, Matulionis N, Schmid EW, Momcilovic M, Sen C, Langerman J, Ramaiah A, Shackelford DB, Damoiseaux R, French SW, Plath K, Gomperts BN, Arumugaswami V, Christofk HR. SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition. *Nat Commun* 2021;12:1876.
- [7] Moloney PB, Delanty N. Stick or twist: everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic. *Seizure* 2021;91:271–2.
- [8] Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. *Pediatr Neurol* 2013;49:255–65.
- [9] Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshé SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. *Epilepsia* 2017;58:512–21.
- [10] Lu L, Zhang Q, Xiao J, Zhang Y, Peng W, Han X, Chen S, Yang D, Sander JW, Zhou D, Xiong W. COVID-19 vaccine take-up rate and safety in adults with epilepsy: data from a multicenter study in China. *Epilepsia* 2022;63:244–51.
- [11] Pollizzi KN, Patel CH, Sun IH, Oh MH, Waickman AT, Wen J, Delgoffe GM, Powell JD. mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation. *J Clin Investig* 2015;125:2090–108.
- [12] Mannick JB, Morris M, Hockey HP, Roma G, Beibel M, Kulmatycki K, Watkins M, Shavlakadze T, Zhou W, Quinn D, Glass DJ, Klickstein LB. TORC1 inhibition enhances immune function and reduces infections in the elderly. *Sci Transl Med* 2018;10:1564.